Literature DB >> 17937937

The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.

Spencer E Harpe1, Sheryl L Szeinbach, Robert J Caswell, Ron Corey, James W McAuley.   

Abstract

PURPOSE: Patient decisions to seek treatment for overactive bladder are influenced by the impact of the condition on health related quality of life and the presence of prescription insurance coverage. This study uses conjoint analysis to examine the relative importance of health related quality of life dimensions of the overactive bladder questionnaire and the presence of prescription insurance coverage on patient preference for treatment.
MATERIALS AND METHODS: Patient preferences were elicited using a study questionnaire that included 9 hypothetical profiles containing an orthogonal array of attributes relating to coping with symptoms, symptom concern, sleep disturbances, problems with social interactions and prescription insurance coverage. This questionnaire was administered to 150 patients with self-reported symptoms of overactive bladder. Patients responded to each profile with the likelihood that they would prefer drug therapy to control overactive bladder symptoms versus doing nothing.
RESULTS: A total of 133 usable responses were obtained from participants. Analysis was conducted with a linear random effects model. Of the 5 included attributes prescription insurance coverage was the most important attribute followed by sleep disturbances, symptom concern, social interaction problems and coping. Responses obtained from attribute ratings using visual analog scaling and a holdout profile demonstrated study validity.
CONCLUSIONS: Prescription insurance coverage and sleep disturbances are important considerations underlying patient preferences for the treatment of overactive bladder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937937     DOI: 10.1016/j.juro.2007.08.006

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial.

Authors:  Kirill Vladimirovich Kosilov; Sergey Loparev; Irina Kuzina; Olga Shakirova; Nataliya Zhuravskaya; Alexandra Lobodenko
Journal:  Ther Adv Urol       Date:  2016-06-03

2.  Comparison of diary-derived bladder and sleep measurements across OAB individuals, primary insomniacs, and healthy controls.

Authors:  Xavier A Preud'homme; Cindy L Amundsen; George D Webster; Andrew D Krystal
Journal:  Int Urogynecol J       Date:  2012-08-02       Impact factor: 2.894

3.  Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.

Authors:  Kirill Vladimirovich Kosilov; Loparev Sergay Alexandrovich; Kuzina Irina Gennadyevna; Shakirova Olga Viktorovna; Zhuravskaya Natalia Sergeevna; Ankudinov Ivan Ivanovich
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

4.  Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.

Authors:  Kirill Vladimirovich Kosilov; Sergay Alexandrovich Loparev; Irina Gennadyevna Kuzina; Boris Izrailevich Geltser; Olga Viktorovna Shakirova; Natalya Sergeevna Zhuravskaya; Alexandra Lobodenko
Journal:  Investig Clin Urol       Date:  2017-02-01

5.  Influence of current state of executive function and working memory on adherence to antimuscarinic therapy in older women with OAB.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Ekaterina Kosilova
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-07-27

6.  Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study.

Authors:  Mikolaj Przydacz; Tomasz Golabek; Przemyslaw Dudek; Marek Lipinski; Piotr Chlosta
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.379

7.  Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons.

Authors:  Kirill Vladimirovich Kosilov; Sergey Loparev; Irina Kuzina; Alexandra Prokofyeva
Journal:  Ther Adv Urol       Date:  2017-10-05

8.  Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument.

Authors:  Sheryl L Szeinbach; Enrique Seoane-Vazquez; Kent H Summers
Journal:  Patient Prefer Adherence       Date:  2012-08-31       Impact factor: 2.711

Review 9.  Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.

Authors:  Crisanta I Tapia; Kristin Khalaf; Karina Berenson; Denise Globe; Michael Chancellor; Lesley K Carr
Journal:  Health Qual Life Outcomes       Date:  2013-01-31       Impact factor: 3.186

10.  Testing for allergic disease: parameters considered and test value.

Authors:  Sheryl L Szeinbach; Spencer E Harpe; P Brock Williams; Hanaa Elhefni
Journal:  BMC Fam Pract       Date:  2008-08-26       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.